Stratus

Stratus Therapeutics is a biotechnology company developing a proprietary platform for off-the-shelf, universal hematopoietic stem cell (HSC) therapies. By utilizing its Stratus Prime platform, the company generates transgene-free, durable HSCs and hematopoietic progenitor cells (HPCs) from induced pluripotent stem cells (iPSCs), effectively mimicking the natural development of the blood system. Their lead candidate, ST-101, is designed to restore full blood and immune function without the need for matched donors, aiming to eliminate the wait times and compatibility risks associated with traditional bone marrow transplants. The technology leverages a breakthrough in mechanobiology involving the chemical activation of the PIEZO1 ion channel to produce self-renewing stem cells. Headquartered in Cambridge, Massachusetts, the company is advancing a pipeline of therapies targeting severe hematological and immunological disorders.